Maynard Um
-
-
-
-
-
-
-
Jefferies stays Buy on Nektar Therapeutics (NKTR) after Rezpeg data hits upside estimates, sees 10-30% stock move into Ph3
-
-
-
-
-
-
-
Wedbush Starts Nektar Therapeutics (NKTR) at Neutral
-
-
-
-
-
-
-
Nektar reports positive REZOLVE-AD maintenance data for atopic dermatitis drug
-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) PT Raised to $121 at Jefferies
-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) PT Raised to $99 at Jefferies
-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) Announces Proposed Public Offering
-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) to Resume Trading at 8 am
-
404,872 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

